Drugs / DLL3 CAR-NK cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05507593 | Sep 2022 → Mar 2023 | small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07172412 | Nov 2025 → Dec 2027 expected | small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DLL3-CAR-NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05507593 ↗ |
| Modality | Cell therapy | “Biological: DLL3-CAR-NK cells” NCT05507593 ↗ |
| Route | Other | “given a single infusion of DLL3-CAR-NK cells injection” NCT05507593 ↗ |
| Target | DLL3 | “DLL3 CAR-NK cells” NCT07172412 ↗ |